Dara-SVD vs. Dara-RVD
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 70 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Selective Inhibiton of Nuclear Export (SINE), Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1823
- NCT Identifier
- NCT06169215
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.